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Abstract
Radiotherapy (RT) is the backbone of multimodality treatment of more than half 
of cancer cases. Despite new modern RT techniques, late complications may occur 
such as radiation proctitis (RP). The natural history of RP is unpredictable. Minor 
symptoms may resolve spontaneously or require conservative treatment. On the 
other hand, for similar and uncomplicated clinical contexts, symptoms may 
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persist and can even be refractory to the progressive increase in treatment 
measures. Over the last decades, an enormous therapeutic armamentarium has 
been considered in RP, including hyperbaric oxygen therapy (HBOT). Currently, 
the evidence regarding the impact of HBOT on RP and its benefits is conflicting. 
Additional prospective and randomised studies are necessary to validate HBOT’s 
effectiveness in the ‘real world’ clinical practice. This article reviewed the relevant 
literature on pathophysiology, clinical presentation, different classifications and 
discuss RP management including a proposal for a therapeutic algorithm with a 
focus on HBOT.
Key Words: Radiation proctitis; Radiation proctopathy; Radiotherapy; Radio-induced 
lesion; Late radiation tissue injury; Delayed radiation injury; Late sequelae; Hyperbaric 
oxygen therapy; Hyperbaric oxygen; Review
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Core Tip: Over the last decades, an enormous therapeutic armamentarium has been 
considered in radiation proctitis (RP) management including hyperbaric oxygen 
therapy (HBOT). However, evidence regarding the impact of HBOT on RP and its 
benefits is conflicting. With the lack of consensus to guide the use of HBOT for the 
treatment of RP, the goal of this review was to synthesise the existing data, analyse 
results of previous studies, identify gaps in knowledge, and discuss RP’ management 
including a proposal of a therapeutic algorithm focusing on HBOT.
Citation: Alpuim Costa D, Amaro CE, Nunes A, Cardoso JS, Daniel PM, Rosa I, Branco JV. 
Hyperbaric oxygen therapy as a complementary treatment for radiation proctitis: Useless or 




In recent years and on a global scale, we have witnessed a sustained increase of cancer 
incidence, with a steady growth rate of approximately 3% per year. According to the 
International Agency for Research on Cancer of the World Health Organization, it is 
estimated that worldwide the number of new cancers will reach almost 30 million in 
2040, with a mortality of 16.5 million[1].
However, these alarming numbers may be related to the implementation of 
screening programs with the detection of more cases of cancer at an early stage. 
Moreover, the survival rates of patients diagnosed with cancer have also increased, 
largely due to scientific development and the commitment of health professionals in 
oncology. The progressive increase of this new population cancer survivors with 
specific clinical and social problems poses a real healthcare challenge. It is in this 
particular context that radio-induced lesions arise, taking into account their prevention 
and treatment.
In developed countries, radiotherapy (RT) is the backbone of multimodality 
treatment of more than half of cancer cases. Despite new modern RT techniques, 
delayed radiation injury can appear with a latency period of a few months to several 
decades. The incidence and prevalence of radio-induced lesions and their severity are 
not well known due to different definitions, underestimation of mild symptoms by 
both patients and professionals, and the imprecise notification of their appearance in 
clinical practice[2].
RT is a key treatment of the multimodal approach of neoplasms of the gastro-
intestinal and pelvic regions. The fixed anatomical position of the rectum in the pelvic 
brim and the proximity to the irradiated organs makes the rectum especially vulne-
rable to secondary ionising radiation injury[3]. Radiation proctitis (RP) or radiation 
proctopathy is defined as a chronic lesion of the mucosa and submucosa of the rectum 
or rectosigmoid transition secondary to ionising radiation[3].
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Acute radio-induced lesions occur from hours or days after exposure to ionising 
radiation and usually resolve in less than 3 mo. On the other hand, RP is a late lesion 
with a median onset of 6 to 12 mo after exposure. Rare cases with a latency over 30 
years have been reported. Furthermore, RT can develop a continuous process from an 
acute injury, where symptoms are not specific or non-existent. The clinical pre-
sumption is based on intestinal symptoms (e.g., haematochezia, diarrhoea, tenesmus, 
abdominal pain) and in a cause-effect relationship of previous history of pelvic RT. 
The diagnosis can be confirmed by endoscopy with or without histologic examination, 
as imaging findings are usually nonspecific[4-12].
Virtually all patients will experience some clinical manifestation of acute RP during 
their pelvic RT treatment[8]. Previously, it was thought that only a minority of patients 
(5%-15%) would develop RP[9,13,14]. However, based on recent data, it is now 
estimated that near half of the patients may report symptoms related to RP[14,15]. 
Following RT, 30% of patients with prostate cancer, 12%-17% with rectal cancer, 16% 
with testicular cancer and 10% with cervical cancer will develop RP[16]. RP’s most 
severe cases have an estimated 4.3%-22% incidence and a 2%-8% mortality rate[11-16].
A high risk of developing RP depends on the total radiation dose and its frac-
tionation, the mode of application (external vs intracavitary), the volume of irradiated 
tissue and the combination of RT techniques. A cumulative dose of RT < 45 Gy is 
associated with a lower risk of late RT lesion in contrast to what is observed for doses 
> 70 Gy, for which the risk is significantly higher. The RT technique used is an 
essential predictor of risk for RP. Compared to brachytherapy, ionising radiation 
typically administered through a linear accelerator will result in greater and more 
significant exposure of the contiguous organs. The new RT modalities that comprise 
three-dimensional conformational RT, intensity-modulated RT and proton and 
neutron therapies seem to be associated with a lower risk of gastrointestinal toxicity[5-
9,17,18].
Advanced age, low body mass index, smoking habits, previous abdominal surgery 
due to intraperitoneal adhesions, pelvic inflammatory disease, arterial hypertension, 
diabetes mellitus, previous chemotherapy, collagen and vascular diseases, xeroderma 
pigmentosa, Cockayne syndrome are other patient-related factors that may be 
associated with a higher RP risk. Among this array of risk factors, those that seem to 
have the most significant predictive value for RP are the history of abdominal surgery, 
chemotherapy, arterial hypertension, and thinness[5-13].
Although the processes of obliterating endarteritis, hypoxia, and fibrosis are already 
recognised as fundamental factors for their establishment and eventual evolution to 
chronicity, RP’s pathophysiology is complex and has not yet been fully understood[12,
19-21]. This chronic condition can stabilise or gradually worsen with periods of acute 
inflammation.
The beneficial properties of hyperbaric oxygen, together with the growing know-
ledge about the pathophysiology of delayed radiation injuries, have led to the use of 
hyperbaric oxygen therapy (HBOT) in the treatment of RP[4]. Currently, HBOT is 
considered by the European Committee for Hyperbaric Medicine (ECHM) as a 
treatment modality for late radio-induced lesions, namely, the prevention and 
treatment of osteoradionecrosis of the mandible, haemorrhagic radiation cystitis and 
RP (degree of recommendation I/level of evidence B). Although HBOT is used in 
selected cases of other RT sequelae (e.g., central nervous system and radio-induced 
laryngeal lesion), its degree and level of recommendation/evidence is lower[22].
Attending to the lack of consensus on guidelines for the use of HBOT in the 
treatment of RP, the goal of this review is to synthesise the existing data, analyse 
results of previous studies, identify gaps in knowledge, and discuss RP’ management 
including a proposal for a therapeutic algorithm with a focus on HBOT.
RP PATHOPHYSIOLOGY 
Ionising radiation can cause cellular damage, especially in mucosa with rapid renewal 
such as the intestinal mucosa.
Acute lesions occur predominantly in the mucosa, which consists of depletion of 
epithelial cells due to cytotoxicity in progenitor cells and consequent apoptosis; 
inflammation and infiltration of the lamina propria with polymorphonuclear leuko-
cytes and plasma cells; eosinophilic abscesses of intestinal crypts; endothelial lesions of 
intestinal microvascularisation and eventual oedema of the submucosa. These 
processes result in mucositis that interferes with the intestinal barrier’s function, 
allowing antigen translocation including microorganisms[23]. If the submucosa 
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modifications are not impactful, the epithelial cells regenerate and the process resolves 
spontaneously (Figure 1).
Parallel to what has been described for other late sequelae of RT, RP’s pathophy-
siological mechanisms are not fully understood. Oxidative stress caused by reactive 
oxygen species (ROS) contributes to obliterating endarteritis with progressive 
reduction of parietal irrigation and consequent local ischaemia, formation, and diffuse 
progression of mucosal and submucosal fibrosis through a local proinflammatory 
cytokines cascade (high levels of interleukin-1β (IL-1β), IL-2, IL-6, IL-8, and trans-
forming growth factor-β), which is promoted by macrophages, neutrophils, and by the 
differentiation of fibroblasts into myofibroblasts (Figures 1 and 2)[5,23-25]. Recently, 
an unique intestinal microbiota signature has been identified in an animal model of 
RP, which seems to be capable of increasing the expression of IL-1β, IL-6, and tumour 
necrosis factor-α (Figure 2). Mice colonised with previously irradiated intestinal mi-
crobiota were more prone to RP than the control colonised with naïve intestinal 
microbiota[26]. Furthermore, it is postulated that the microbiota can also influence the 
efficacy of the cancer treatment per se.
This transmural pathological regenerative process of the intestinal wall will exa-
cerbate the progressive decrease in vascular density (and consequently the formation 
of friable telangiectasias and lymphatic vessels dilation), cell depletion, mucosal 
atrophy, and stenosis of the intestinal wall. Moreover, chronic mucosal ulcers can 
predispose to haemorrhage, the formation of fistulae and possible risk of intestinal 
perforation (Figure 2)[6,8,9].
CLINICAL PRESENTATION
Clinically, RP presents itself in two forms: acute or chronic. The acute form is typically 
resolved within a few weeks and it is characterised by nausea, vomiting, abdominal 
pain, diarrhoea, urgency, tenesmus, and more rarely, lower gastrointestinal bleeding. 
The chronic form has a similar clinical presentation; however, it is characterised by an 
indelible evolution, leading, in the most severe cases, to major digestive haemorrhage, 
chronic constipation, faecal incontinence, severe proctalgia, stenosis, fistulisation and 
eventually, intestinal perforation. Moreover, patients may also have other symptoms 
resulting from pelvic irradiation such as radiation enteritis, haemorrhagic radiation 
cystitis or urethral stricture. The occurrence of colorectal neoplasms induced by 
radiation has also been described, mostly after a long latency period, which can be 
manifested by masses or non-healing ulcers[5,7,8].
For diagnosis, a cause-effect relationship should be established between the history 
of pelvic RT and intestinal symptoms. A rectal examination will evaluate anal 
sphincter tonicity and a rectosigmoidoscopy the mucosa characteristics and affected 
areas, excluding malignancy. Total colonoscopy can be considered to outline the true 
extent of the disease and/or exclude the possibility of another aetiology for colitis. 
Endoscopic images usually reveal a pale, friable mucosa, with telangiectasias and/or 
ulcerations, and a clear separation between the altered and normal region, corres-
ponding to the irradiated zone’s limit. A biopsy is usually not recommended to 
confirm the diagnosis because it may increase the risk of complications[7,8].
In addition, it is essential to exclude other possible causes of subacute or chronic 
proctitis such as inflammatory bowel disease, diverticular colitis, atherosclerotic 
disease or previous episodes of chronic ischemic colitis, chronic exposure to the effects 
of non-steroidal anti-inflammatory drugs, recent use of antibiotics that predispose to 
Clostridioides difficile infection, parasitic (e.g., amebiasis) or bacterial (e.g., Salmonella 
spp., Campylobacter spp.) infections due to recent travelling to endemic countries, 
history or risk factors for sexually transmitted diseases (e.g., Neisseria gonorrhoeae and 
herpes simplex virus) and cytomegalovirus infection in the immunocompromised 
patient[7,8].
In several studies, the severity of RP is objectively graded using symptom scores, 
such as the Radiation Proctopathy System Assessment Scale or the Late Effects Normal 
Tissue (LENT-SOMA) scale and considering the intraluminal findings by endoscopic 
grade (modified Chi grading or scales Chutkan and Gilinski). The comparison of data 
between studies is difficult due to the use of different severity scores. The same is true 
for outcome measures. Table 1 summarises some of the different classifications of RP 
that have been proposed in the literature[27-37].
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Table 1 Classification of stages/grades of radiation proctitis
Ref. Stages/grades Description
Sherman[27], 1954 I-IV Based on endoscopic findings: I: (a) Localised erythema and telangiectasia, friable mucosa with easy 
bleeding: no ulceration or stricture formation, and (b) More diffuse erythema along with periproctitis, 
marked pain, and sensitivity; II: Presence of ulceration with a greyish tenacious slough, usually 
involving the anterior rectal wall, and proctitis with grade I lesions; III: Presence of rectovaginal 
fistulae or bowel perforation and varying degrees of proctitis with ulceration; IV: Presence of 
rectovaginal fistulae or bowel perforation and varying degrees of proctitis with ulceration.
Dean and Taylor[28], 1960 I-III Based on clinical and endoscopic findings: I: Symptoms: Rectal bleeding, tenesmus, sphincter 
instability, mucoid discharge; endoscopic findings of vascular congestion, friability of the mucosa, 
mucosal thickening, mucoid discharge; II: Same symptoms as before; endoscopic findings of 
ulcerations, underlying thrombosis of the small vessels; III: Same symptoms as before plus perineal 
sepsis, incontinence, diarrhoea, perianal purulent discharge; endoscopic findings of necrosis, fistulae, 
strictures.
Gilinsky et al[29], 1983 Normal; Mild; 
Moderate; Severe
Based on endoscopic findings: Score 0: Normal mucosa; Score 3: Erythema and/or telangiectasia, 
oedema, thickening, pallor of mucosa; Score 6: Friability; Score 9: Ulceration and/or necrosis.
Langberg et al[30], 1992 1-3 Based on histopathologic findings: Thickening of serosa: (1) Slight thickening of serosa, hyperplasia of 
peritoneal mesothelium; and (2) Marked thickening of serosa; and (3) Extreme thickening and fibrosis 
serosa. Mucosal alterations: (1) Small superficial ulcerations; and (2) Ulcerations involving more than 
half of the intestinal circumference. Epithelial atypia: (1) Abnormally oriented crypts; (2) Irregular 
crypt regeneration with atypical epithelial cells; and (3) Adenocarcinoma. Vascular sclerosis: (1) Slight 
double normal thickness, broadened and hyalinised collagen fibres; (2) Submucosa three to four times 
normal thickness, abnormal collagen fibres; and (3) Massive fibrosis including muscularis. Lymph 
congestion: (1) Dilated lymph vessels or cystic collections of lymph. Ileitis cystica profunda: (1) 
Submucosal glandular inclusions; (2) Submucosal cysts with polypoid elevation of the mucosa; and (3) 
Large cysts extending into the muscularis.
Chutkan et al[31], 1997 0-4 Based on clinical findings: 0: No haemorrhage; 1: Blood on toilet paper or mixed with faeces; 2: Drops 
of blood in the toilet; 3: Severe haemorrhage with expulsion of clots; 4: Haemorrhage that requires 
transfusion.
Wachter et al[32], 2000. 
Vienna Rectoscopy Score
0-5 Based on endoscopic findings: Score 0: Congested mucosa (grade 1); Score 1: Congested mucosa 
(grade 2), telangiectasia (grade 1); Score 2: Congested mucosa (grade 3), telangiectasia (grade 2); Score 
3: Congested mucosa (any grade), telangiectasia (grade 3), ulceration (grade 1); Score 4: Congested 
mucosa (any grade), telangiectasia (any grade), ulceration (grade 2), stricture (grade 1); Score 5: 
Congested mucosa (any grade), telangiectasia (any grade), ulceration (grade  3), stricture (grade  2), 
necrosis (any grade).
Zinicola et al[33], 2003. 
Bleeding Scale for Radiation-
Induced Haemorrhagic 
Proctitis
0-4 Based on clinical findings: 0: No bleeding; 1: Intermittent bleeding (once weekly or less); 2: Persistent 
bleeding (twice or more weekly); 3: Daily bleeding or anaemia; 4: Require blood transfusion.
Chi et al[34], 2005. RTD 
grading scale
0-3 Based on RTD endoscopic findings: 0: Normal mucosa; 1: < 10 telangiectasias; 2: > 10 telangiectasias; 3: 
Confluent lesions, active bleeding or friable mucosa.
Ehrenpreis et al[35], 2005. 
Radiation Proctopathy System 
Assessment Scale (RPSAS)
1-5 Based on clinical findings: Diarrhoea. Urgency. Rectal pain. Tenesmus. Rectal bleeding. Faecal 
incontinence. Severity: 1: No problem. 2: Mild problem–can be ignored when you do not think about 
it. 3: Moderate problem–cannot be ignored; no effect on ADL. 4: Severe problem–influences your 
concentration on ADL. 5: Very severe problem–markedly influences your ADL and/or requires rest. 
Frequency: 1: Monthly; 2: Weekly; 3: Several times per week; 4: Daily; 5: Throughout the day.
Cox et al[36], 1995. Late 
Radiation Morbidity Scoring 
Criteria Radiation Therapy 
Oncology Group/European 
Organisation for Research and 
Treatment of Cancer
0-5. Late (> 3 mo) Based on clinical and imaging findings: 0: No changes; 1: Mild diarrhoea, mild cramping, bowel 
movement 5 times daily, slight rectal discharge or bleeding; 2: Moderate diarrhoea or colic, bowel 
movement > 5 times daily, excessive rectal mucus or intermittent bleeding; 3: Obstruction or bleeding 
requiring surgery; 4: Necrosis, perforation, or fistulae; 5: Death related to adverse event.
NCI CTCAE version 5.0[37], 
2017
1-5 Based on clinical findings: 1: Mild adverse event; rectal discomfort, intervention not indicated; 2: 
Moderate adverse event; rectal discomfort, passing blood or mucus, medical intervention indicated, 
limiting instrumental ADL; 3: Severe and undesirable adverse event, faecal urgency or stool 
incontinence, limiting self-care ADL; 4: Life-threatening or disabling adverse event, urgent 
intervention needed; 5: Death related to adverse event.
ADL: Activities of daily living; RTD: Rectal telangiectasia density.
RP TREATMENT
The treatment of acute RP is essentially symptomatic and in accordance with the 
guidelines for the treatment of mucositis of other aetiologies[38,39]. In the absence of 
response to first-line antidiarrheal medication, it must be recommended treatment 
with octreotide or other somatostatin analogues and butyrate enemas that seem to 
accelerate the intestinal mucosa regeneration process. There is clinical evidence that 
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Figure 1 Representative scheme of intestinal injury induced by ionising radiation. In a healthy gut, crypts are with intact mucosa. Lgr5+ stem cells 
proliferate and cells migrate upwards to provide differentiated epithelial cells of the villi. Acute lesions occur predominantly through different pathological processes: 
Depletion of epithelial cells due to cytotoxicity in progenitor cells and consequent apoptosis; inflammation and infiltration of the lamina propria with polymorphonuclear 
leukocytes and plasma cells; eosinophilic abscesses of intestinal crypts; endothelial lesions of intestinal microvascularisation with the release of thrombin and 
eventual oedema of the submucosa; influx of antigenic material, including gut microbiota into the lamina propria. If the submucosa modifications are not impactful, the 
epithelial cells regenerate, and the process resolves spontaneously. The constitutive and chronic phase comprises obliterating endarteritis with progressive reduction 
of parietal irrigation and consequent local ischaemia; formation and diffuse progression of mucosal and submucosal fibrosis through a local proinflammatory cytokine 
cascade (high levels of interleukin-1β (IL-1β), IL-2, IL-6, IL-8, and transforming growth factor-β), which is promoted by macrophages, neutrophils and by the 
differentiation of fibroblasts into myofibroblasts. Citation: Adapted from Costa et al[21] and Kumagai et al[23].
intrarectal amifostine (ROS scavenger) could be, in selected patients, a possible 
protective pharmacological measure against the acute effects of RT. Generally, the 
acute RP is a self-limiting situation, although in about 20% of cases, it is necessary to 
suspend or even interrupt RT treatments[7,38,39].
The natural history of RP per se is unpredictable. Minor symptoms may resolve 
spontaneously or require conservative treatment. On the other hand, symptoms may 
persist for similar and uncomplicated clinical contexts and become refractory to the 
progressive increase in therapeutic intervention. Thus, early diagnosis and inter-
vention are essential and symptoms should not be overlooked, even if they have little 
impact on the patient’s quality of life (QoL).
The management of RP can be challenging and requires a holistic approach for 
which there is no gold standard protocol. Furthermore, there are no prophylactic 
measures that have been shown to be beneficial in reducing RP incidence. Concerning 
treatment options, most of the clinical evidence is based on case studies and small 
series. Therapeutic management should be personalised according to the patient, the 
severity of the clinical condition, and the institution’s experience. The non-invasive or 
minimally invasive measures include changing the diet and symptom control with 
pharmacological and endoscopic support. In terms of medical treatment, the 
intrarectal application of formalin (4%-10% formaldehyde) and sucralfate enemas 
stand out as effective measures to control bleeding in patients with haemorrhagic RP. 
Studies present conflicting results for the use of short-chain fatty acid enemas. There is 
a lack of scientific evidence to recommend the use of alternative treatments such as 
mesalamine, ozone therapy, metronidazole, vitamin A, antioxidant vitamin complexes 
(vitamin C and E) and pentoxifylline. Endoscopic treatment with plasma argon has 
been effective in controlling and treating lower gastrointestinal bleeding. Endoscopic 
bipolar electrocoagulation, radiofrequency ablation, Nd: YAG laser and cryotherapy 
are possible alternatives to argon, although their evidence level is low. Despite the 
enormous therapeutic armamentarium, the more severe RP cases may require 
radiological intervention for lower gastrointestinal bleeding and surgical intervention, 
especially in complications such as effective control of lower gastrointestinal bleeding, 
fistulisation, occlusion, and intestinal perforation[3,5,7,8,38,39].
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Figure 2 Representative scheme of the several pathophysiological mechanisms involved in radiation proctitis: The hypoxia/hypocel-
lularity/hypovascularisation, intestinal microbiota and the fibroatrophic theories. FGFb: Basic fibroblast growth factor; IGF1: Insulin-like growth 
factor 1; IL: Interleukin; INF-β: Interferon- beta; PDGF: Platelet-derived growth factor; ROS: Reactive oxygen species; TGF-β1: Transforming growth factor beta-1; 
TNF-α: Tumour necrosis factor-alpha. Citation: Adapted from Costa DA et al[21].
HBOT
HBOT is a treatment based on the inhalation of pure oxygen (100%) in an environment 
with an atmospheric pressure higher than that existing at sea level (1 atmosphere 
absolute [ATA]). The HBOT sessions are held inside hermetically sealed hyperbaric 
chambers, classified as type IIb medical devices (directive 93/42 ECC of June 14, 1993, 
concerning medical devices). HBOT is used in several clinical conditions as well as in 
professional and military training. Therapeutic HBOT usually involves pressures 
higher than 1.4 ATA (141.8 kPa), most frequently ranging between 2.0 (202.6 kPa) and 
2.5 ATA (253.3 kPa) for 60 to 120 min[40].
Currently, the ECHM recommends HBOT for the treatment of RP (degree of 
recommendation I/ level of evidence B)[22]. Unlike most conventional treatment that 
only alleviated symptoms, HBOT can favourably change the natural history of other 
RT late sequelae[4]. Its clinical benefit emanates from the therapeutic effects of 
hyperbaric oxygen that include, among others, the promotion of tissue oxygenation, 
neovascularisation, reepithelialisation, and the reversal of the fibroatrophic process 
induced by ionising radiation[16,21,41,42].
The mechanisms that result in HBOT beneficial effects can also cause side effects in 
some patients, primarily due to pressure and oxygen toxicity. However, when 
appropriate therapeutics protocols are applied, HBOT is a safe and low-risk inter-
vention, with the adverse events being infrequent and typically not severe[40-43].
In 1991, Charneau et al[44] treated the first RP patient with HBOT. The 74-year-old 
patient had a 5-mo history of transfusion-dependent haemorrhagic RP. For this 
patient, after the failure of previous treatments (enema with corticosteroids and Nd: 
YAG laser), HBOT was considered a strategy to avoid surgery. After 82 sessions of 
HBOT (2.5 ATA, for 90 min, twice daily), a complete clinical response was observed, 
which remained during the follow-up period of at least 9 mo. After this pioneering 
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report, others were published, including case reports, retrospective, (non)-randomised 
studies and clinical trials, as well as several reviews and meta-analyses that studied 
the clinical impact of HBOT on RP (Table 2)[16,45-71]. However, most studies had both 
a small number of cases treated and a short follow-up period.
In 1997, Warren et al[47] conducted a study with 14 patients undergoing two 
pressurisation regimens (n = 9; 2 ATA, for 120 min, 5-6 times per week; n = 5; 2.35 
ATA, for 90 min, 5 times per week). The authors documented an overall response rate 
of 64.3% (57.1% with complete responses) for an average follow-up period of 14.6 
(range 2-35) mo. In the same year, Woo et al[48], published a study with 18 patients 
submitted to 24 sessions of HBOT (2 ATA, for 105 min, 6 times per week) with a 
follow-up period of 14 (range 3-65) mo. In this study, different response rates were 
reported according to the symptoms analysed: Haemorrhage 41.2% (7/17); rectal pain 
50% (2/4); incontinence 75% (3/4) and diarrhoea 50% (4/8). Furthermore, most 
patients (77.7%) had already undergone other treatments but with little clinical benefit 
(n = 13, enema with corticosteroids; n = 1, formalin). Gouëllo et al[52], published a 
study with 36 patients submitted to an average of 67 sessions of HBOT (2.5 ATA, for 
90 min, 5 times per week). An overall response rate of 53% (19/36) was observed 
immediately after the end of treatment. In the 52-mo follow-up period, the overall 
response rate was 66% (21/32). In 2002, in a systematic review published by Feldmeier 
and Hampson[2], 14 publications were evaluated in the context of RP and radiation 
enteritis (12 studies in humans and 2 in animals). Of the 9 studies, 114 patients were 
considered, and an overall response rate of 95.6% was documented (36%, 41 patients 
with complete response; 60%, 68 patients with better symptomatic control). Despite 
these studies have shown an improvement in RP with HBOT, a clinical benefit has also 
been verified in the small intestine radio-induced malabsorption syndrome. In 2007, 
Marshall et al[16], published the largest study carried out up to that time, with 65 
patients with enteritis and RP (85% of patients). The authors described an overall 
response rate of 68% (43% with complete responses) after at least 30 sessions of HBOT 
(2.4 ATA, for 90 min, 5 times per week). However, half of the patients (49.2%, 32) had 
to be submitted to more HBOT sessions, up to a maximum of 60, due to partial 
response or recurrence of symptoms. The mean follow-up time was 23 (range 1-70) 
mo. The response rate of patients with low gastrointestinal bleeding was 70%. In those 
dependent on transfusions, the response rate was very satisfactory since 75% of these 
patients no longer needed transfusion support. For symptoms other than haemo-
rrhage, the response rate was 58%, with pain reduction, nutritional status impro-
vement, intestinal transit regularisation and even fistulae closure. Moreover, no 
correlation was established between the treatment response rate and the duration of 
symptoms or the time between RT and initiation of HBOT.
In 2008, Clarke et al[65] published the results of the first multicentre, randomised, 
sham-controlled, double-blind clinical trial (HORTIS) that included patients with RP 
refractory to other therapeutic interventions. A total of 150 patients were enrolled, but 
only 120 completed the study. Patients were randomised to HBOT (Group 1: 2.0 ATA, 
for 90 min, 5 times per week) or sham treatment with 21% oxygen (Group 2: 1.34-> 1.1 
ATA, for 90 min, 5 times per week). The clinical response evaluation was performed 
after 30 treatment sessions, with the possibility of 10 additional sessions, depending on 
the investigator’s decision. Only 3 patients did not accept the crossover to the active 
arm of the initial HBOT (Group 1). After adjusting covariates and for an average 
follow-up period of 2 years, Group 1 significantly improved the mean LENT-SOMA 
score (5.00 vs 2.61, P = 0.0019). In the initial allocation phase and after the first efficacy 
assessment, the experimental group’s overall response rate was higher than in the 
control group (88.9% vs 62.5%, P = 0.0009). Furthermore, there was also a significant 
improvement in QoL (pattern of pain, bleeding and intestinal transit) in Group 1 
(including in the crossover subgroup of patients). It is noteworthy that, for Group 1, 
the improvement in QoL in terms of faecal incontinence, faecal urgency, pain and 
intestinal transit was consistent throughout the follow-up period. In 2015, Tahir et al
[69] reported an overall response rate of 95% in the 59 patients treated with RP (51% of 
patients with complete response for a median duration of 15 mo). Bennett et al[72], in a 
Cochrane meta-analysis published in 2016, documented a significant increase in the 
clinical improvement or even remission of RP after HBOT (relative risk 1.72; 95% 
confidence interval 1.0-2.9, P = 0.04, NNT to benefit 5).
In 2016, Glover et al[70], in a multicentre, randomised, double-blind, sham-
controlled phase 3 trial (HOT2), evaluated the clinical benefit of HBOT in patients with 
chronic bowel dysfunction after RT in the context of pelvic neoplasms. Treatment 
efficacy was determined by comparing the Inflammatory Bowel Disease Questionnaire 
(IBDQ) and the IBDQ rectal bleeding scores assessed before and 12 mo after starting 
treatment. Moreover, other secondary endpoints were evaluated: LENT-SOMA, the 
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Table 2 Summary of the case-series or clinical trials described in the literature regarding the use of hyperbaric oxygen therapy in the 
treatment of radiation proctitis

























Retrospective 8 NA 100% 2.5 ATA, 90 
min, twice 
daily (4 wk)-> 
Once daily




Retrospective 7 RTOG/EORTC[36]: 
4
28.6% 2.4 ATA, 90 
min, 5 ×/wk
24 [3-50] 57% 57% NA
Warren et 
al[47], 1997
Retrospective 14 Bleeding (n = 11); 
Diarrhoea (n = 5); 
Rectal pain (n = 4); 
Tenesmus (n = 2)
78.6% 2.0 ATA, 120 
min, 5-6/wk; 
2.35 ATA, 90 
min, 5 ×/wk




Retrospective 18 Bleeding (n = 17); 
Diarrhoea (n = 8); 
Rectal pain (n = 4); 
Incontinence (n = 4)
77.7% 2.0 ATA, 105 
min, 6 ×/wk
24 [40] 55.5%; 
Incontinence 
75%; Diarrhoea 













Retrospective 19 NA NA 2.36 ATA, 90 
min, 5 ×/wk
30 84% 47% NA
Ugheoke et 
al[50], 1998
Retrospective 8 NA NA 2.5 ATA, 90 
min, 5 ×/wk
28 [20-40] 62.5% NA NA
Carl et al
[51], 1998
Retrospective 2 Bleeding (n = 1); 
Rectal pain (n = 1)
NA 2.4 ATA, 90 
min, 5 ×/wk
38, 40 50% 50% NA
Gouëllo et 
al[52], 1999
Retrospective 36 LENT-SOMA: 
Grade 1 (n = 1); 
Grade 2 (n = 11); 
Grade 3 (n = 16); 
Grade 4 (n = 8) 
NA 2.5 ATA, 90 
min, 5 ×/wk
67 (mean) 66% 25% 52
Kitta et al
[53], 2000
Retrospective 4 Bleeding (n = 3); 
Rectal pain (n = 1)







Retrospective 2 Dean and Taylor
[28]: I-II
100% 2.4 ATA, 90 
min, 5 ×/wk
60, 60 100% 100% [3-48]
Roque et al
[55], 2001
Retrospective 6 NA NA 2.5 ATA, 90 
min, 5 ×/wk
37 [20-60] 85% NA NA
Mayer et al
[56], 2001
Retrospective 10 RTOG/EORTC[36]: 
Grade 2 (n = 4); 
Grade 3 (n = 6)
Majority (% 
not stated)
2.2-2.4 ATA, 60 
min, 7 ×/wk




Retrospective 19 NA NA 2.0 ATA, 120 
min, 5 ×/wk
59 [27-80] 68% NA NA
Jones et al
[58], 2006
Retrospective 10 LENT-SOMA: 
Grade 2 (n = 7); 
Grade 3 (n = 3)
100% 2.0-2.5, 90 min, 
5 ×/wk










Retrospective 27 RTOG/EORTC[36]: 
3-4
100% 2.4 ATA, 90 
min, 7-7 ×/wk
36 [29-60] 66.6%; 
Haemorrhage 










Retrospective 4 NA 100% 2.4 ATA, 90 
min, 5 ×/wk
31 [28-37] 75% 25% 33




Retrospective 9 100% 2.5 ATA, 90 
min, 5 ×/wk
58 [22-80 100% 77.7% 17 [1-77]
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Haemorrhagic 
Proctitis[33]: Grade 
2 (n = 1); Grade 3 (n 
= 3); Grade 4 (n = 5)
Marshall et 
al[16], 2007




Bleeding (n = 54); 
Diarrhoea (n = 25); 
Rectal pain (n = 25); 
Tenesmus, urgency, 
incontinence (n = 
13); Malnutrition, 
weight loss (n = 7); 
Bloating, cramping 
(n = 6); Nausea, 
emesis (n = 5); 
Fistulae (n = 2); 
Total parenteral 
nutrition (n = 2)

































HBOT, mean 7.7 ± 
2.0; Control, mean 
6.8 ± 2.3. Karnofsky 
scale: HBOT, mean 
73.8 ± 6; Control, 





















Retrospective 6 NCI CTCAE[37]: 
Mean 3.3 [2-4]


















HBOT, mean 12.55; 
Sham, mean 12.84
100% HBOT, 2.0 
ATA, 90 min, 5 
×/wk vs Sham 
treatment 1.34-
> 1.1 ATA O2 
21%, 90 min, 5 
×/wk

























HBOT, 12.1 ± 2.9; 
APC, 13.3 ± 2.9
NA HBOT 2.0-2.5 







rate at 60 W, 
mean 3 ± 1 (SD) 
sessions
HBOT, 35 
± 5 vs 
APC, 3 ± 1





Retrospective 4 LENT-SOMA: Mean 
0.66 [0.36-0.93]. 
Severity of rectal 
bleeding: Persistent 
(n = 3), Occasional (
n = 1) 








Retrospective 30 NA NA 2.5 ATA, 100 
min, 5 ×/wk
66 [38-80] 96.7% 73.3% NA
Tahir et al
[69], 2015
Retrospective 59 NA NA 2.4 ATA, 70 
min, 7x/wk












(n/IQR): HBOT 48 
(42-52); Sham 51 




(n/IQR): Δ 3.5 (-
3-11). IBDQ 
rectal bleeding 
(n/IQR): Δ 3 (1-














100% HBOT 2.4 ATA, 
90 min, 5 ×/wk 
vs Sham 
treatment 1.34 
ATA O2 21%, 
90 min, 5 ×/wk
40 (89% of 
patients) 
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bleeding (n/IQR): 
HBOT 3 (2-4); Sham 
3 (2-4). NCI CTCAE
[64]: Grade 1-3, 46 
(55%). EORTC 
QLQ-CR38 




(n/IQR): Δ 4 (-6-
9); IBDQ rectal 
bleeding 





Retrospective 5 Sherman[27]: Grade 
II (n = 3); Grade III (
n = 1); Grade IV (n = 
1)





APC: Argon plasma coagulation; ATA: Atmosphere absolute; HBOT: Hyperbaric oxygen therapy; IBDQ: Inflammatory Bowel Disease Questionnaire; IQR: 
Interquartile range; min, minute; NA: Not available or not applicable; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse 
Events; O2: Oxygen; QoL: Quality of life; RP: Radiation proctitis; SD: Standard deviation; Δ: Median change from baseline to 12 mo.
11-question questionnaire related to symptoms selected from the CTCAE gastro-
intestinal scale (version 4.0) and QoL through validated questionnaires (Questionnaire 
basic EORTC QLQ-C30 and colorectal module QLQ-CR38). Patients of both sexes with 
ages over 18 years were included, with at least grade 2 gastrointestinal symptoms of 
any category of LENT-SOMA or grade 1 with intermittent symptoms due to RT 
performed at least 12 mo before in the context of rectal, prostate, testicle, bladder, 
cervix, vagina, vulva or ovary neoplasms. Patients with grade 3 symptoms LENT-
SOMA were excluded since they have higher affectation on activities of daily living 
and require, generally, more aggressive treatments. Patients with RT symptoms were 
considered eligible for the trial only if they had been submitted to other general 
interventions for at least 3 mo (e.g., diet change, oral therapeutic optimisation) with no 
improvement. Patients were randomised in a 2:1 ratio in favour of HBOT and stratified 
by centre. Patients were randomised to HBOT (2.4 ATA, for 90 min, 5 times per week) 
or 21% oxygen (1.3 ATA, for 90 min, 5 times per week). Of the 84 patients included in 
this clinical trial, 55 underwent HBOT and 29 sham treatment. In the analysis of 
clinical efficacy, no difference was identified between the two arms, when comparing 
the main endpoints: IBDQ bowel component [HBOT = 46; sham treatment = 23; HBOT: 
4 (-3 to 11) vs sham treatment: 4 (-6 to 9), P = 0.50] and IBDQ rectal bleeding [HBOT = 
29; sham treatment = 11; HBOT: 3 (1 to 3) vs sham treatment: 1 (1 to 2), P = 0.092].
The results of the HOT2 clinical trial are inconsistent with most previous clinical 
evidence, including the Cochrane meta-analysis[72], primarily based on the HORTIS
[65] clinical trial. The HOT2 study[70] is a very relevant clinical trial from a methodo-
logical point of view: Phase 3, randomisation 2:1, stratification by centre, double-blind, 
sham-controlled, with primary and secondary endpoints with previously validated 
scores and questionnaires and with well-defined inclusion/exclusion criteria, in-
cluding a period of at least 3 mo for possible symptom optimisation and control. 
However, one can enumerate some aspects that can be criticised (not only exclusively 
for this trial): (1) The sample size is debatable for a phase 3 clinical trial when it is 
supposed to comprises a total number of patients over 300. The statistical calculation 
was based on assumptions defined and validated in previous studies. However, the 
comparison between the two arms was performed with an insufficient number of 
patients (HBOT: 46 vs sham treatment: 23); (2) The drop-out rate was 17.86% (15 
patients: 9 from the HBOT group and 6 from sham treatment), with only 69 out of 84 
patients having a 12-mo follow-up period. The final statistical power was 75%, 
although the study had been designed for 80% power; (3) Patients with symptoms ≥ 
grade 3 LENT-SOMA (e.g., severe faecal incontinence or transfusion-dependent RP) 
were not included. Thus, one cannot generalise the results for this subgroup; (4) It is 
unknown whether the percentage of patients with a medical history of lower 
gastrointestinal bleeding influences their progress during the study (HBOT: 62% vs 
sham treatment: 79%); (5) The dietary and/or pharmacological measures performed in 
the period prior to randomisation were not discriminated (e.g., diet type, probiotics, 
antibiotic cycles). Did these different procedures influence the natural history of the 
disease and the potential response to treatment? (6) The smoking habits of the patients 
were not quantified. Otto et al[73], in a study on diabetic foot, determined that patients 
with above a 10 pack-year (P-Y) history of smoking would need an average of more 
than 8 to 14 sessions of HBOT to obtain the same therapeutic effect as non-smokers. 
Freiberger et al[74] reported that in patients with mandible osteoradionecrosis, those 
who smoked showed a shorter maintained treatment period response to HBOT when 
compared to non-smoking patients (15.8 vs 86.1 mo). The stratification by smoking 
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Figure 3 Suggested treatment algorithm for radiation proctitis based on variables related to the patient, institution, and the severity of the 
clinical context. RP: Radiation proctitis; RT: Radiotherapy.
habits could have been relevant in this trial (non-smoker or smoker ≤10 P-Y vs >10 P-
Y); (7) The distribution of the subgroup of patients (n = 9; 11%) who did not complete 
the 40 treatment sessions in both arms of the clinical trial is unknown; (8) The 
endoscopic response to the recommended treatments is unknown; (9) The clinical and 
endoscopic evolution beyond the median follow-up period 13.2 (range 12.4-14.2) is 
also unknown. In HORTIS clinical trial[65] it was observed and additional and 
maintained response beyond 12 mo of the follow-up period; and (10) The absence of a 
third arm in the study comparing HBOT to another conventional treatment for RP.
We recommend that HBOT, combined with nutritional support and local treatment, 
may be beneficial for patients with moderate to severe symptoms that do not require 
surgical intervention. The HBOT regimen should include at least 20-30 sessions with a 
pressure of 2 to 2.5 ATA for 60 to 120 min/d to ensure a more effective clinical 
response. The treatment protocol total duration may be extended to several weeks 
until a clinical and radiological complete response is obtained, and the follow-up 
should be personalised to each clinical context, considering a period of 2 to 5 years 
(Figure 3).
CONCLUSION
Although there are several effective therapeutic strategies to treat RP and improve its 
clinical condition, gold standard management has not yet been established. RP’s 
management approach must be personalised according to the patient, clinical 
condition severity, and the institution’s experience. The most conservative treatment 
comprises diet modulation and nutritional support, oral and intrarectal pharmaco-
logical treatment and HBOT. Endoscopic treatment may be indicated for the control 
and treatment of lower gastrointestinal bleeding. In severe refractory disease with 
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complications, surgical intervention should be considered.
During HBOT, the occurrence of adverse events is relatively infrequent. HBOT may 
potentially alleviate gastrointestinal radio-induced complications, including rectal 
bleeding, diarrhoea and pain. The authors’ expectancies are that, in the near future, the 
controversy regarding HBOT in RP will be dimmed. More prospective and rando-
mised studies are needed to validate the effectiveness of HBOT in the ‘real-world’ 
clinical practice.
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